Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)

As new public health challenges relating to COVID-19 emerge, such as variant strains, waning vaccine efficacy over time, and decreased vaccine efficacy for special populations (immunocompromised hosts), it is important to determine a correlate of protection (CoP) to allow accurate bridging studies f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, Amy C., Desjardins, Michaël, Baden, Lindsey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563351/
https://www.ncbi.nlm.nih.gov/pubmed/35153045
http://dx.doi.org/10.1016/j.cll.2021.10.008
_version_ 1784593400786321408
author Sherman, Amy C.
Desjardins, Michaël
Baden, Lindsey R.
author_facet Sherman, Amy C.
Desjardins, Michaël
Baden, Lindsey R.
author_sort Sherman, Amy C.
collection PubMed
description As new public health challenges relating to COVID-19 emerge, such as variant strains, waning vaccine efficacy over time, and decreased vaccine efficacy for special populations (immunocompromised hosts), it is important to determine a correlate of protection (CoP) to allow accurate bridging studies for special populations and against variants of concern. Large-scale phase 3 clinical trials are inefficient to rapidly assess novel vaccine candidates for variant strains or special populations, because these trials are slow and costly. Defining a practical CoP will aid in efficiently conducting future assessments to further describe protection for individuals and on a population level for surveillance.
format Online
Article
Text
id pubmed-8563351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85633512021-11-03 Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection) Sherman, Amy C. Desjardins, Michaël Baden, Lindsey R. Clin Lab Med Article As new public health challenges relating to COVID-19 emerge, such as variant strains, waning vaccine efficacy over time, and decreased vaccine efficacy for special populations (immunocompromised hosts), it is important to determine a correlate of protection (CoP) to allow accurate bridging studies for special populations and against variants of concern. Large-scale phase 3 clinical trials are inefficient to rapidly assess novel vaccine candidates for variant strains or special populations, because these trials are slow and costly. Defining a practical CoP will aid in efficiently conducting future assessments to further describe protection for individuals and on a population level for surveillance. Elsevier Inc. 2022-03 2021-11-03 /pmc/articles/PMC8563351/ /pubmed/35153045 http://dx.doi.org/10.1016/j.cll.2021.10.008 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sherman, Amy C.
Desjardins, Michaël
Baden, Lindsey R.
Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title_full Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title_fullStr Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title_full_unstemmed Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title_short Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
title_sort vaccine-induced severe acute respiratory syndrome coronavirus 2 antibody response and the path to accelerating development (determining a correlate of protection)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563351/
https://www.ncbi.nlm.nih.gov/pubmed/35153045
http://dx.doi.org/10.1016/j.cll.2021.10.008
work_keys_str_mv AT shermanamyc vaccineinducedsevereacuterespiratorysyndromecoronavirus2antibodyresponseandthepathtoacceleratingdevelopmentdeterminingacorrelateofprotection
AT desjardinsmichael vaccineinducedsevereacuterespiratorysyndromecoronavirus2antibodyresponseandthepathtoacceleratingdevelopmentdeterminingacorrelateofprotection
AT badenlindseyr vaccineinducedsevereacuterespiratorysyndromecoronavirus2antibodyresponseandthepathtoacceleratingdevelopmentdeterminingacorrelateofprotection

Ejemplares similares